Drug pipeline selected content

Lipocene anticipates the phase 3 trial data will support an NDA submission for LPCN 1154 to treat PPD in mid-2026, the company said.

Clinical insights on cannabis and dementia, hormonal contraceptives and postpartum depression, the FDA-approved blood test for Alzheimer disease, more.

The new, 7-member committee was clear on its support for the mAb for infants and the essential role of vaccination against influenza but wants an alternative preservative to thimerosal.

Discover the latest breakthroughs in clinical research, from at-home cancer screening to AI advancements in mammography, shaping future healthcare practices.

Suboptimal adherence with antidementia drugs is associated with poorer clinical outcomes including accelerated disease progression and symptomatology.

ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.